Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study

Table 2

Efficacy outcomes.

Variable	Group		Rivaroxaban (86)	Warfarin (42)		value
Reexamination after 1 month	Disappeared	49	37 (43.02%)	12 (28.57%)	1.5396	0.2147
	Effective	46	30 (34.88%)	16 (38.1%)	0.0810	0.7760
	No effect or progressed	10	6 (6.98%)	4 (9.52%)	0.2343	0.6283
	Reappear	0	0 (0%)	0 (0%)
	—	23	13 (15.12%)	10 (23.81%)
Reexamination after 3 months	Disappeared	69	52 (60.47%)	17 (40.48%)	2.0916	0.1481
	Effective	34	22 (25.58%)	12 (28.57%)	0.0950	0.7579
	No effect or progressed	12	7 (8.14%)	5 (11.9%)	0.4267	0.5136
	Reappear	0	0 (0%)	0 (0%)
	—	7	5 (5.81%)	8 (19.05%)	0.0571	0.8111